Background and Purpose-This study investigated the safety and tolerability of desmoteplase administered within 3 to 9 hours after stroke symptoms onset in Japanese patients with acute ischemic stroke. Methods-Patients were randomized to treatment with either desmoteplase or placebo in a 2:1 ratio in 2 consecutive cohorts (70 μg/kg and then 90 μg/kg). Included patients had a baseline National Institutes of Health Stroke Scale score of 4 to 24 and occlusion or high-grade stenosis in the middle cerebral artery segment M1 or M2 on magnetic resonance angiography. The incidence of symptomatic intracranial hemorrhage (≤72 hours) was defined as the primary end point. The occurrence of asymptomatic ICH, symptomatic cerebral edemas, and adverse events were other safety outcomes of special interest. Results-Symptomatic intracranial hemorrhage was observed within 72 hours in 2 patients treated with placebo and in 1 patient treated with 70 μg/kg desmoteplase. Any ICH (symptomatic or asymptomatic ICH) within 72 hours were observed in 7 (43.8%) patients treated with placebo, in 8 (50%) patients treated with 70 μg/kg desmoteplase, and in 9 (56.3%) patients treated with 90 μg/kg desmoteplase. Desmoteplase treatment with 70 or 90 μg/kg was not associated with an increased risk of symptomatic cerebral edema compared with placebo. There were no other serious safety concerns associated with desmoteplase. Conclusions-Desmoteplase in both 70 and 90 μg/kg doses had a favorable safety profile and was well tolerated in Japanese patients with acute ischemic stroke when administered 3 to 9 hours after stroke symptoms onset. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01104467. 
T he only thrombolytic intervention currently approved for treatment of acute ischemic stroke (AIS) in Japan is alteplase. Japanese open-label studies led to the use of a lower dose of alteplase in Japan and in some other countries of the region compared with that approved in other countries. [1] [2] [3] [4] [5] [6] At the time of planning and initiation of Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke (DIAS-J) study, the administration of alteplase in Japan was limited within 3 hours after symptoms onset because the benefit-risk ratio of treatment with alteplase in the later time after stroke symptoms onset becomes negative.
This time limit was extended ≤4.5 hours in August 2012. Yet, there is an unmet need for patients who present beyond these time limits.
Desmoteplase tested in Phase II and III clinical trials for treatment of AIS within 3 to 9 hours after symptoms onset [7] [8] [9] is a fibrin-dependent plasminogen activator, which potentially could result in a lower risk of intracerebral bleeding. Desmoteplase does not increase blood-brain barrier permeability in preclinical models. 10 Further, clinical data in AIS patients indicate that desmoteplase is associated with a low risk of brain hemorrhage and high rates of early reperfusion.
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As there is a concern of increased intracranial hemorrhage (ICH) associated with thrombolytics in far-east Asians, this phase II study was designed to provide information on the safety and tolerability of 2 doses of desmoteplase (70 and 90 μg/kg) in Japanese patients with AIS in an extended time window of 3 to 9 hours after stroke symptoms onset.
Methods
Study Design and Patients
We undertook a randomized, double-blind, placebo-controlled, doseescalation study enrolling 48 patients from 18 sites located throughout Japan. Eligible patients were men and women aged between 20 and 85 years with a clinical diagnosis of AIS who could be treated in the 3 to 9 hours' time window. The patients had a baseline National Institutes of Health Stroke Scale (NIHSS) score of 4 to 24, with clinical signs of hemispheric infarction. Only certified raters performed the NIHSS ratings. Included patients presented with a proximal cerebral artery occlusion or high-grade stenosis, on magnetic resonance angiography, in the middle cerebral artery (MCA) segment M1 or M2. Patients with infarction on magnetic resonance imaging involving >1/3 of the MCA territory were excluded.
A full list of selection criteria is available in the online-only Data Supplement.
The trial was developed and conducted in accordance with the principles of the Declaration of Helsinki, and each site initiated patient inclusion only after Ethics Committee approval. Written informed consent was obtained from all patients or from their legal representatives, as appropriate.
Randomization, Masking, Sample Size, and Dose-Escalation
Eligible patients were randomized to treatment with either desmoteplase or placebo in a 2:1 ratio in 2 consecutive cohorts (cohort 1: 70 μg/kg, then cohort 2: 90 μg/kg) using an interactive voice/web response system (IXRS). The system used computer-generated randomization lists. Patients, investigators, staffs, and the funder were masked to treatment assignment. Study drugs were supplied in vials (identical in appearance) containing lyophilized powder dissolved for injection of either desmoteplase or placebo.
A total sample size of 48 patients was planned for the study, 24 in each of the consecutive cohorts, resulting in 16 patients in each dose group. Patients treated with placebo in cohorts 1 and 2 were pooled in the analyses. As the study was designed to give a safety signal, not to detect differences, no formal sample size calculations were performed. Nevertheless, the number of patients was selected to achieve an acceptable balance between the Type I error (the risk of stopping the study if desmoteplase is safe, symptomatic intracranial hemorrhage [sICH] ≤8%) and the power (probability of stopping if unsafe, sICH >8%). Based on Monte Carlo simulations with 50 000 replications, the safety monitoring controls the overall Type I error at 16% when the true sICH rate is ≤8% and has 78% power to detect an alternative sICH rate of 20% given the sample size of 16+16 patients on active treatment.
An independent Data Monitoring Committee monitored safety on an ongoing basis and had access to unblinded data. Escalation from a treatment dose of 70 to 90 μg/kg desmoteplase was based on Data Monitoring Committee recommendation as guided by monitoring boundaries from a predefined sICH rate, as well as on an overall safety evaluation. All other committees made their assessments blinded to treatment group.
Procedures
Patients underwent 2 scheduled brain imaging assessments during the study: a scanning at baseline and at 18±6 hours after study medication administration. Additional brain imaging was obtained if part of clinical practice or if the patient experienced neurological deterioration of ≥4 points on the NIHSS. Baseline magnetic resonance imaging sequences included a T2*-weighted sequence to identify patients with ICH, a T2*-weighted fluid attenuation inversion recovery sequence to 54 screened for eligibility Only patients with TIMI 0 and 1 at baseline were included in analyses of recanalization. The primary end point was the presence of sICH within 72 hours after administration of study medication according to the central retrospective review performed by the Adjudication Committee. The term symptomatic referred to an ICH that was associated with a clinical worsening of ≥4 points on the NIHSS. Safety outcomes of special interest included asymptomatic ICH defined as an ICH which did not fulfil the clinical criteria for a sICH, symptomatic cerebral edema defined as extending infarction with mass effect confirmed by appropriate diagnostic imaging which results in a worsening of ≥ 4 points on the NIHSS as evaluated by the Adjudication Committee, mortality, and adverse events (AEs). Data on (1) minor hemorrhagic events-defined as an anemia or bleeding episode other than ICH and not life-threatening-and (2) major hemorrhagic events-defined as an anemia or bleeding episode other than ICH, which was considered to be life-threatening-were based on a clinical evaluation by the investigators.
Exploratory efficacy end points were the modified Rankin Scale (mRS) score at Day 90 (favorable outcome defined as mRS score 0-2). Only certified raters performed the mRS ratings. Exploratory end points also included the change from baseline on the NIHSS at Day 90, and NIHSS response to treatment at Day 90 defined as an improvement of at least 8 points from baseline or a final score of ≤1.
A detailed description of committees involved in the study and a full list of protocol-specified end points and study procedures/assessments are available in the online-only Data Supplement.
Statistical Analysis
This study was planned for randomization with a replacement rule in case a patient had been randomized but not treated and, therefore, prespecified to use the All Patients-Treated Set defined as the set of patients who were randomized and received the study medication for safety or the full analysis set (FAS) defined as all patients in the APTS who had at least one valid postbaseline assessment of the mRS for efficacy.
AEs were coded using the lowest-level term according to Medical Dictionary for Regulatory Activities, Version 16.0.
The data from the clinical assessments, including demographics and other baseline characteristics of the patients, are summarized by treatment using descriptive techniques. Summary statistics (number of observations, mean, standard deviation) are presented for changes from baseline and absolute values, whereas counts and percentages are presented for categorical variables.
The Freeman-Halton extension of Fisher exact test was used to compare the sICH proportions among groups. The significance level was set to a 2-sided P=0.05.
The statistical software used was SAS, Version 9.4.
Results
From August 2010 to May 2013, 54 patients were screened, of whom 49 were randomized, whereas 5 patients were ineligible according to the study criteria ( Figure) . In cohort 1, a total of 16 patients received desmoteplase (70 μg) and 8 patients received placebo. The safety sICH monitoring boundary was never crossed at any time during the study, thus no safety signal aroused, and after review of Cohort 1 safety data by the Data Monitoring Committee, a further 16 patients received desmoteplase 90 μg and 8 patients received placebo (Cohort 2). Of the 17 patients randomized to placebo, 1 patient who was randomized to placebo but found to be not eligible for the study (recanalization detected on a second magnetic resonance imaging before administration) was replaced and was not included in the full analysis set, and 3 patients were withdrawn (1 death and 2 lost to follow-up). Of the 32 patients randomized to desmoteplase, all received study medication: 1 patient was lost to follow-up (desmoteplase 70 μg) and 1 patient died (desmoteplase 90 μg). Baseline demographics and clinical characteristics are shown in Table 1 . For 11 of the 48 dosed patients, the Imaging Committee found that the patients did not meet imaging criteria, with no occlusion or severe stenosis in the MCA (M1/M2) being the Min, Max 4, 9 4, 9 5, 9
Prestroke mRS score was assessed by investigator by asking patient or relatives. APTS indicates all patients-treated set; DSPA, desmoteplase; mRS, modified Rankin scale; NIHSS, National Institute of Health Stroke Scale; PBO, olacebo; TIMI, Thrombolysis in Myocardial Infarction.
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September 2015 most frequent deviation (3, 3, and 1 patients in the placebo, the 70 μg/kg, and the 90 μg/kg desmoteplase groups, respectively). The Imaging Committee also determined that 0, 2, and 1 patients in the placebo, the 70 μg/kg, and the 90 μg/kg desmoteplase groups, respectively, had a lesion >1/3 of MCA territory. According to the review by the Adjudication Committee, in the period ≤72 hours after study medication, there were 2 patients with sICH in the placebo group, 1 patient in the desmoteplase 70 μg/kg group, and no patients with sICH in the desmoteplase 90 μg/kg group ( Table 2) . The difference among groups was not significant (P=0.76). One placebo-treated patient developed symptomatic cerebral edema within 72 hours as assessed by the Adjudication Committee. There were no additional sICH and cerebral edema beyond 72 hours after study medication in either group (Table 2 ). All the sICHs were of type 2 parenchymal hemorrhage, and all of the asymptomatic ICHs were of other type than type 2 parenchymal hemorrhage. In the period from study medication ≤90 days, all 3 groups presented equal numbers, 11 in each group, of any ICH (ie, sICH + asymptomatic ICH)
An overview of noncerebral minor and major hemorrhagic events within 72 hours is presented in Table I in the onlineonly Data Supplement. Only minor noncerebral hemorrhagic events were observed up to this time point in 4 (25%), 6 (38%), and 6 (38%) patients in the placebo group, the 70 μg/kg, and the 90 μg/kg desmoteplase groups, respectively. During the 90 days study period, minor noncerebral hemorrhagic events were somewhat more common in the desmoteplase-treated groups than in the placebo group: 6 (38%), 10 (63%), and 12 (75%) patients in the placebo group, the 70 μg/kg, and the 90 μg/kg desmoteplase groups, respectively. There was one major noncerebral hemorrhagic event (postoperative anemia) in the desmoteplase 70 μg/kg-treated group. Noncerebral hemorrhagic events within 90 days are shown in Table II in the online-only Data Supplement.
Serious AEs were reported for 9 patients with numbers balanced across treatment groups (placebo, 4 events; desmoteplase 70 μg/kg, 2 events; desmoteplase 90 μg/kg, 3 events). Two patients died during the study period: one in the placebo group because of gastric cancer, 55 days post dose, whereas the second death occurred in the desmoteplase 90 μg/kg group because of chronic cardiac failure, 10 days post dose. There were 6 patients with serious AEs within the system organ class nervous system disorders (4 patients in the placebo group and 1 patient in each of the desmoteplase groups). By preferred term, brain edema was the only serious AE occurring in >1 patient (2 patients in the placebo group and 1 patient in the 90 μg/kg desmoteplase group). The detailed list of serious AEs up to Day 90 is presented in Table  III in the online-only Data Supplement.
The total number of AEs observed within 90 days is shown in Table 3 . All patients experienced ≥1 AE during the study (placebo, 114 events; desmoteplase 70 μg/kg, 126 events; desmoteplase 90 μg/kg, 136 events). The most common AEs are listed in Table IV in the online-only Data Supplement. AEs with a higher incidence in the desmoteplase group over the placebo group included γ-glutamyltranseferase increased (placebo, 0 patients; desmoteplase 70 μg/kg, 2 patients; desmoteplase 90 μg/ kg, 4 patients), hemorrhage subcutaneous (placebo, 0 patients; desmoteplase 70 μg/kg, 2 patients; desmoteplase 90 μg/kg, 2 patients), and pyrexia (placebo, 1 patients; desmoteplase 70 μg/ kg, 3 patients; desmoteplase 90 μg/kg, 3 patients).
Effects of treatment on exploratory efficacy end points are shown in Table 4 . In the group of patients treated with the 90 μg/kg desmoteplase, 11 out of 16 (68.8%) achieved a Day 90 mRS score of 0 to 2 versus only 7 (43.8%) in the placebo-treated group. Recanalization was achieved in 5 patients treated with placebo and in 6 and 6 patients treated with 70 and 90 μg/kg desmoteplase, respectively (see Table 4 ).
Discussion
The main finding from the study was that treatment with either of 2 doses of desmoteplase was not associated with AEs were judged by the investigators. AEs indicates adverse events; APTS, all patients-treated set; DSPA, desmoteplase; PBO, placebo; and SAEs, serious adverse events.
*Death 10 days after study medication. †Death 55 days after study medication. an increased occurrence of sICH, ICH overall, or symptomatic cerebral edema compared with placebo. The prevalence of sICH in either desmoteplase arm was comparable to that in J-ACT II MCA occlusion cohort treated with 0.6 mg/kg alteplase within 3 hours of onset as well as that in DIAS-3 90 mg/kg desmoteplase cohort. 5, 11 The moderately higher rate of minor hemorrhagic events, observed for patients in the desmoteplase-treated groups relative to placebo, is expected considering the administration of a thrombolytic compound. There was no indication of mortality being affected by desmoteplase treatment.
The study was not powered to provide proof of efficacy. Nevertheless, numerically higher response rates were obtained for desmoteplase as compared with placebo at Day 90. The recanalization rates from baseline to 18 hours after study medication administration were comparable across treatment groups. In any event, the baseline characteristics varied between the treatment groups: the median age was higher in the placebo group than in the 2 desmoteplase groups; the median NIHSS score at baseline was higher in the placebo group than in the 2 desmoteplase groups; time from symptoms onset to study medication was lowest in the placebo group. These differences should be considered when interpreting the results because these factors could impact outcome after stroke.
Overall, we conclude that the study demonstrated a favorable safety and tolerability of desmoteplase in Japanese patients when administered 3 to 9 hours after ischemic stroke onset. Despite of our concerns based on alteplase experience, we did not see that the higher dose of desmoteplase was associated with higher incidence of sICH. These findings extend our understanding of AIS treatment in the late time window and a potential role of fibrin-dependent plasminogen activating agents. Specifically, the present study provides data on Japanese patients who are currently treated with a lower dose of alteplase, suggesting that thrombolytics with high fibrin specificity are safe in these patients even with major artery occlusion/severe stenosis and treated in the extended time window.
The relatively high number of patients enrolled, but subsequently determined to have deviated from the imaging criteria, suggests that imaging assessment of early ischemic tissue injury and recognition of major intracranial cerebral artery obstruction is challenging. 
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Safety and tolerability of desmoteplase within 3-9 hours after symptoms onset in Japanese patients with acute ischemic stroke (DIAS-J)
Protocol specified selection criteria
Inclusion criteria
 Clinical diagnosis of acute ischemic stroke  Informed Consent  Male or female and aged between 20 and 85 years inclusive  Treatment within 3-9 h of the onset of stroke symptoms  NIHSS score of 4-24 inclusive with clinical signs of hemispheric infarction  Cerebral artery occlusion or high-grade stenosis on MRA in MCA M1 or M2 that corresponds to the acute clinical deficit  Patient must receive study medication within 60 minutes after completion of the last diagnostic imaging sequence.
Exclusion criteria
 Pre-stroke mRS score of >1 (indicating previous disability)  Previous exposure to desmoteplase  Participation in an investigational study within the previous 90 days  A terminal illness with a life-expectancy of less than 6 months  Any condition that could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study  NIHSS score > 2 on question 1a (indicating coma)  A history or clinical presentation of ICH, subarachnoid haemorrhage (SAH), arteriovenous malformation (AVM), moyamoya disease, cerebral neoplasm or aneurysm  Symptomatic acute vertebral or basilar artery occlusion  Current use of warfarin or similar oral vitamin K antagonists and a prolonged prothrombin time (INR > 1.6)  Treated with heparin in the previous 48 hours and a prolonged partial thromboplastin time exceeding the upper limit of the local laboratory normal range  Treated with high-dose oral platelet inhibitors in the previous 7 days  Treated with factor Xa inhibitors, direct thrombin inhibitors or any anticoagulants other than those already specified in the past 72 h  Baseline platelet count < 100,000/mm 3  Baseline haematocrit of < 0.25  Baseline blood glucose < 50 mg/dl or >200 mg/dl (< 3 mmol/l or > 11 mmol/l)  Blood pressure >185 mmHg systolic or >110 mmHg diastolic immediately prior to study medication administration (or requiring aggressive treatment to reduce the blood pressure to within these limits)  Hereditary or acquired hemorrhagic diathesis  Gastrointestinal or urinary bleeding within the past 21 days  Arterial puncture in a non-compressible site within the previous 7 days  Stroke or a serious head injury in the past 6 weeks 3  Major surgery or serious injury, including other sites than the head, within the preceding 14 days  Seizure at the onset of stroke  Acute myocardial infarction (AMI) within the previous 3 weeks  Received a thrombolytic within the previous 72 h  Pregnant (positive serum pregnancy test, positive urine pregnancy test or clinically evident pregnancy) or breast-feeding  Unlikely to comply with the clinical study protocol or is unsuitable for any reason, in the opinion of the investigator  Signs of extensive early infarction on MRI involving >1/3 of MCA territory  Evidence of ICH or SAH regardless of age of the bleeding; arteriovenous malformation; cerebral aneurysm; or cerebral neoplasm  Parenchymal hyperintensity on FLAIR, T2*, or EPI-T2 images (indicative of subacute infarction), or enhancement with morphologic features suggesting the lesion is more than 9 hours old  Internal carotid artery occlusion on the same side of the brain as the stroke lesion  Contraindication to MRI (referring to Imaging Manual)  Any intracranial pathology that could interfere with the assessment of the chosen imaging technique for screening
Withdrawal criteria
A patient was withdrawn from the study if:
 Patient or the person who signed on behalf of the patient withdrew his/her consent  Patient was lost to follow-up  Investigator considered it, for safety/efficacy reasons, in the best interests of the patient that he/she was withdrawn  Patient was randomised but the study medication was not administered The date and reason for withdrawal was noted in the Withdrawal Form in the electronic case report form (eCRF). All patients who withdrew from the study were, if at all possible, seen for a Withdrawal Visit scheduled as soon as possible after withdrawal from the study. Patients withdrawn before administration with study medication were replaced. For patients who withdrew their consent, only data up until the time of withdrawal of consent were used. 4
Protocol specified endpoints Primary Endpoint
• The presence of symptomatic intracranial haemorrhage (sICH) within 72 hours after study medication
Secondary Endpoints
Safety Endpoints
• sICH, asymptomatic ICH (aICH), symptomatic cerebral oedema, major bleeding complications; mortality; adverse events, clinical safety laboratory tests, vital signs, ECG, physical examination 
Committees involved in the Study
The Data Monitoring Committee (DMC) consisted of clinical stroke experts, including a stroke epidemiologist, and a biostatistician. The DMC ascertained that ethical principles were followed and monitored the safety of the patients.
The Imaging Committee (IC) consisted of neuroradiological experts in the field of stroke who prepared the imaging protocol for the study, trained participating study sites, and assessed neuroimaging, following central reading, for imaging eligibility criteria (post study medication), imaging efficacy endpoints, and safety (intracranial haemorrhage; ICH) for all scans performed during the study (scheduled scans + scans performed due to the clinical status of the patient).
The Adjudication Committee (AC) consisted of clinical stroke specialists and neuroradiologists who evaluated all cases of neurological worsening, defined as increase of 4 points or more in NIHSS score at any time from lowest score, and all deaths to determine causality and potential relation to study medication. 
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